SCYNEXIS to Present Data from Lead Antifungal Drug Candidate SCY-078 at 13th ASM Conference on Candida and Candidiasis Apr 6, 2016
SCYNEXIS, Inc. Receives FDA Fast Track and QIDP Designations for Intravenous Formulation of SCY-078 for the Treatment of Patients with Invasive Fungal Infections Jan 28, 2016
SCYNEXIS, Inc. Initiates Enrollment of the Phase 2 Study of SCY-078 in Vulvovaginal Candidiasis Dec 1, 2015
SCYNEXIS, Inc. Announces Initiation of Phase 1 Clinical Trial Evaluating Intravenous Formulation of SCY-078 Nov 12, 2015
